Hormonal Therapies Underused for GSM in Menopause
Hormonal therapies for genitourinary syndrome of menopause (GSM) are underutilized, with significant disparities in access. Research indicates that socioeconomic factors play a role in the likelihood of receiving treatment. The removal of a boxed warning by the FDA last year may help address some barriers to prescribing these therapies.
- ▪Only 55.4% of eligible patients with GSM received hormonal therapy after diagnosis.
- ▪Patients receiving therapy were more likely to be White, have higher education, and earn over $100,000 annually.
- ▪Untreated patients faced higher odds of delaying care due to transportation and rural location issues.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/top-factors-driving-underuse-hormone-therapy-genitourinary-2026a1000fz6?src=rss |
| Publication time | Mon, 18 May 2026 07:50:11 EDT |
| Retrieval time | 2026-05-18T12:04:56.488Z |
| Last seen | 2026-05-18T12:04:56.488Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | Uo3sgFLJEvPR |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Hormonal therapies are indicated for genitourinary syndrome of menopause (GSM), but the therapies are underused and access is inequitable, new data presented as a poster at the American Urological Association (AUA) 2026 Annual Meeting indicate.GSM, which includes vulvovaginal dryness, genital pain from intercourse, and genitourinary symptoms such as incontinence, can be treated with local vaginal estrogen, vaginal dehydroepiandrosterone, and oral ospemifene.Researchers, led by Isabella K.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
